Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Lifesci Capital to “Strong-Buy” Rating

Lifesci Capital upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

A number of other research analysts have also weighed in on ACRS. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Friday, March 27th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Thursday, March 19th. UBS Group set a $10.00 target price on shares of Aclaris Therapeutics in a report on Thursday, April 16th. Finally, Piper Sandler raised their target price on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.50.

Aclaris Therapeutics Stock Performance

ACRS stock opened at $4.63 on Monday. The firm has a fifty day moving average price of $4.26 and a 200 day moving average price of $3.54. Aclaris Therapeutics has a fifty-two week low of $1.34 and a fifty-two week high of $5.15. The firm has a market cap of $646.63 million, a PE ratio of -8.27 and a beta of 0.76.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%. The firm had revenue of $2.00 million during the quarter, compared to analyst estimates of $1.32 million. On average, equities analysts predict that Aclaris Therapeutics will post -0.63 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard sold 300,000 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total value of $1,359,000.00. Following the completion of the sale, the insider directly owned 13,950,000 shares in the company, valued at $63,193,500. This trade represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently bought and sold shares of the stock. R Squared Ltd bought a new stake in Aclaris Therapeutics in the fourth quarter worth $37,000. AXQ Capital LP bought a new stake in Aclaris Therapeutics in the third quarter worth $27,000. Strs Ohio bought a new stake in Aclaris Therapeutics in the first quarter worth $60,000. CIBC Asset Management Inc bought a new stake in Aclaris Therapeutics in the fourth quarter worth $52,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Aclaris Therapeutics in the fourth quarter worth $53,000. 98.34% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.